Health Care [ 8/12 ] | Biotechnology [ 34/74 ]
NASDAQ | Common Stock
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally.
The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B.
It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis.
The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors.
It has a collaboration agreement with theU. S.
Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E.
Limited.
The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996.
Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 20, 25 | 0.05 Increased by +3.03 K% | 0.04 Increased by +25.00% |
| Nov 7, 24 | 0.12 Increased by +20.00% | 0.11 Increased by +9.09% |
| Aug 6, 24 | 0.08 Increased by +166.67% | 0.06 Increased by +33.33% |
| May 8, 24 | -0.07 Increased by +63.16% | -0.02 Decreased by -250.00% |
| Feb 22, 24 | 0.00 Decreased by -99.64% | -0.01 Increased by +116.00% |
| Nov 2, 23 | 0.10 Decreased by -76.74% | -0.01 Increased by +1.10 K% |
| Aug 3, 23 | 0.03 Decreased by -96.55% | -0.09 Increased by +133.33% |
| May 2, 23 | -0.19 Decreased by -186.36% | -0.13 Decreased by -46.15% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 72.03 M Increased by +29.56% | 7.05 M Increased by +3.12 K% | Increased by +9.79% Increased by +2.38 K% |
| Sep 30, 24 | 80.63 M Increased by +15.99% | 17.59 M Increased by +23.10% | Increased by +21.82% Increased by +6.12% |
| Jun 30, 24 | 73.80 M Increased by +22.48% | 11.39 M Increased by +231.86% | Increased by +15.43% Increased by +170.94% |
| Mar 31, 24 | 50.79 M Increased by +8.24% | -8.72 M Increased by +64.16% | Decreased by -17.17% Increased by +66.89% |
| Dec 31, 23 | 55.60 M Decreased by -69.87% | 219.00 K Decreased by -99.68% | Increased by +0.39% Decreased by -98.93% |
| Sep 30, 23 | 69.51 M Decreased by -58.56% | 14.29 M Decreased by -77.60% | Increased by +20.56% Decreased by -45.95% |
| Jun 30, 23 | 60.25 M Decreased by -76.51% | 3.43 M Decreased by -97.34% | Increased by +5.69% Decreased by -88.66% |
| Mar 31, 23 | 46.92 M Decreased by -58.83% | -24.33 M Decreased by -174.35% | Decreased by -51.85% Decreased by -280.60% |